Qilu Pharma Spain S.L.
2 products tracked · names used in filings: Qilu Pharma Spain S.L.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Mon 31 Aug 2026🇪🇺 Expected EC decisionestimate
Nylaspeg (pegfilgrastim): expected EC decision
Estimated as CHMP opinion (2026-06-25) + 67 days, the standard Commission decision period. Not an official date. · Qilu Pharma Spain S.L. · source
Thu 25 Jun 2026🇪🇺 CHMP positive opinion
Nylaspeg (pegfilgrastim): CHMP positive opinion
Qilu Pharma Spain S.L.; Biosimilar, Additional monitoring · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Nylaspeg pegfilgrastim | Authorised | |
| 🇪🇺 | Rimmyrah ranibizumab | Authorised | 2024-01-05 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.